Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | RRM2 | P31350 | 1/20 | 0.34 |
| ▸ | TERT | O14746 | 2/20 | 0.33 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.32 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6629423 | 0.77 | CCR1 (0.50) | CCR1ALDH1A1RRM2TERTTSHR | |
| SCHEMBL12715713 | 0.76 | CCR1 (0.61) | CCR1ALDH1A1MAPT | |
| SCHEMBL20057394 | 0.75 | TDP1 (0.33) | TDP1 | |
| SCHEMBL1574734 | 0.74 | CCR1 (0.46) | CCR1ALDH1A1RRM2TERTTRIM24 | |
| SCHEMBL3046961 | 0.74 | CCR1 (0.46) | CCR1ALDH1A1RRM2TERTMAPT | |
| SCHEMBL25207516 | 0.74 | CCR1 (0.46) | CCR1ALDH1A1TDP1RRM2TERT | |
| SCHEMBL1979692 | 0.74 | CCR1 (0.46) | CCR1ALDH1A1RRM2TERTTRIM24 | |
| SCHEMBL15104564 | 0.74 | CCR1 (0.46) | CCR1ALDH1A1RRM2TERTTRIM24 | |
| SCHEMBL29953577 | 0.74 | CCR1 (0.46) | CCR1ALDH1A1RRM2TERTTSHR | |
| SCHEMBL20110641 | 0.74 | CCR1 (0.46) | CCR1ALDH1A1TERTTSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183230-A1 | COMPOUNDS CONTAINING BENZOSULTAM | SUZHOU GENHOUSE BIO CO., LTD. (CN) | 2023-06-15 | — | — | US | disclosed |
| US-10005741-B2 | Therapeutic compounds | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2018-06-26 | — | — | US | disclosed |
| US-10005741-B2 | Therapeutic compounds | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2018-06-26 | — | — | US | disclosed |
| US-20180141921-A1 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2018-05-24 | — | — | US | disclosed |
| US-20180141921-A1 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2018-05-24 | — | — | US | disclosed |
| US-9908856-B2 | Therapeutic compounds | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2018-03-06 | — | — | US | disclosed |
| US-9908856-B2 | Therapeutic compounds | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2018-03-06 | — | — | US | disclosed |
| US-20170008859-A1 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2017-01-12 | — | — | US | disclosed |
| US-20170008859-A1 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2017-01-12 | — | — | US | disclosed |
| US-20170008859-A1 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2017-01-12 | — | — | US | disclosed |
| WO-2015130973-A1 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2015-09-03 | — | — | WO | disclosed |
| WO-2015130973-A1 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2015-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170008859-A1 | THERAPEUTIC COMPOUNDS | IAPP, PARK7, NLN | CCR1 3841/4885ALDH1A1 854/4885TDP1 2381/4885 |
| US-20180141921-A1 | THERAPEUTIC COMPOUNDS | IAPP, PARK7, NLN | CCR1 3841/4885ALDH1A1 854/4885TDP1 2381/4885 |
| US-10005741-B2 | Therapeutic compounds | IAPP, PARK7, NLN | CCR1 3841/4885ALDH1A1 854/4885TDP1 2381/4885 |
| US-20230183230-A1 | COMPOUNDS CONTAINING BENZOSULTAM | TBXA2R, TBXAS1, SULT2A1 | CCR1 4211/4885ALDH1A1 299/4885TDP1 3865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.